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Abstract: Tetanus is a vaccine-preventable disease of global importance. When acquired it has a high mortality rate. Screenings of
special subpopulations such as women of childbearing age provide important clues about tetanus vaccination coverage, and tools for
mass protective measures, e.g, protective measures for neonatal tetanus. In addition to its reliability and sensitivity, the main
advantage of a mass-screening tool should be its cost-effectiveness. We aimed to develop a cost-effective and sensitive enzyme-linked
immunosorbent assay (ELISA) that can be used for diagnostic research as well as mass screening purposes for antitetanus antibodies.
Our in-house antitetanus ELISA was validated and tested for its sensitivity and specificity and then compared with a commercially
available kit. The analytical sensitivity of the in-house ELISA was less than 0.008 IU/ml. For the tested concentrations the intra- and
inter-assay coefficients of variation were between 0.8 and 4.1% and between 2.2 and 8.6% respectively. The results demonstrated
that our in-house ELISA is quite sensitive and has a high performance with human sera similar to that of a commercial kit in
determining the antitetanus antibody concentrations and may be used for diagnostic purposes as well as in mass screenings for
tetanus vaccination coverage.
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Introduction
Tetanus is a disease of global importance produced by
the toxin of Clostridium tetani. Its pathogenesis involves
the absorption of preformed toxin or invasion of toxinproducing organisms from contaminated wounds. The
risk of acquiring tetanus increases in certain age groups
and especially in countries where poor sanitary conditions
predispose to umbilical stump contamination (1). Despite
intentions to eradicate it, tetanus remains endemic in
developing countries (2).
Although its diagnosis is made clinically, the
measurement of antitetanus antibodies is of value in
assessing the immune status of individuals at risk of
tetanus infection (3). The determination of antitetanus
antibodies is also of great importance in monitoring the
efficiency of mass vaccination programs (2,4).
Techniques for measuring antitoxin levels vary. The toxin
neutralization (TN) test, performed in vivo and regarded
as the gold standard, is a sensitive test that can detect

very low levels of antitoxin, but it is expensive and
requires well trained personnel. The TN test directly
measures the biological activity of tetanus antitoxin. The
passive hemagglutination (HA) test, ELISA, and the
radioimmunoassay are the in vitro techniques applied for
the detection of antitoxin levels. The HA test has a simple
design and can be conducted in a moderately equipped
laboratory. It shows a relative high correlation with the
TN test but its main disadvantage is its preferential
sensitivity for IgM (4). The ELISA test is commonly used
to determine tetanus antibody titers, and several
modifications have been developed to overcome the
unreliability it may show, especially at low antitoxin
concentrations. Discrepancies between tetanus ELISA and
the TN test have been reported in incomplete vaccination
cases and it has been postulated that the antibodies
during the early course of tetanus immunization may be
of low affinity and low avidity and so are responsible for
binding in ELISA but are not able to neutralize tetanus
toxin (5,6). Besides the indirect ELISA test, competition
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ELISA and the toxin-binding inhibition tests have been
proposed for the evaluation of tetanus immunity (5,7,8).
Time resolved fluorometric immunoassays have also been
developed and applied for the quantitation of antitetanus
toxin levels (9,10). Especially in mass-screening
procedures, a simple, cheap and rapid assay for the
quantitative determination of antitetanus levels is
preferable. For diagnostic purposes the assay should be
sensitive at low concentrations of antibodies.
The present study describes the development of a
biotin-streptavidine ELISA for the sensitive determination
of antitetanus toxin antibody levels in human sera.

Materials and Methods
Tetanus toxoid. Tetanus toxoid at a protein content
of 996 µg/ml was obtained from the Refik Saydam
H›fz›s›hha Institute Vaccine Development Center, Ankara.
Diphtheria toxin. Diphtheria toxin at 440 Limes
flocculation (Lf)/ml (protein content was 1.272 mg/ml)
was obtained from the Refik Saydam H›fz›s›hha Institute
Vaccine Development Center, Ankara.
Tetanus antitoxin. The tetanus antitoxin used in this
study was standard tetanus antitoxin IgG reagent
supplied in a commercially available antitetanus ELISA kit
(Tetanus ELISA, Genzyme Virotech GmbH, Rüsselsheim,
Germany).
Human sera. Human sera were kept at -75 ºC until
the day of study. Forty randomly taken human sera were
used for comparing the commercially available kit with
the in-house antitetanus toxoid ELISA.
Labelling of tetanus toxoid with biotin. Tetanus
toxoid was dialyzed against 0.1 M NaHCO3 pH 7.4 and
then labeled with biotin (Sigma, St Louis, MO, USA) as
described elsewhere (11).
Enzyme-linked
immunosorbent
assay
(ELISA). High binding capacity ELISA plates (Costar,
No: 3590, Corning Incorporated, Corning, NY, USA)
were coated with 100 µl of tetanus toxoid at 2 µg/ml
in 0.05 M carbonate-bicarbonate buffer pH 9.6 (CBB)
by incubating at +4 ºC overnight. After washing 3
times with distilled water, blocking was performed
with 200 µl of PBS containing 3% bovine serum
albumin (BSA) by incubating at +4 ºC overnight,
followed by washing 3 times with PBS containing 0.5%
290

Tween 20 (PBS-T). To each well was added 100 µl of
samples diluted to 1/100 in PBS containing 1%BSA
(PBS-1%BSA) or standards of the commercially
available tetanus antitoxin ELISA kit, followed by
incubation at 37 ºC for 1 h. After incubation, the plates
were washed 3 times with PBS-T and then to each well
was added 100 µl of tetanus toxoid-biotin diluted at
1/5000 in PBS-1%BSA. The plates were incubated for
1 h at 37 ºC and then washed 3 times with PBS-T. To
each well was added 100 µl of streptavidinehorseradish peroxidase (Sigma), followed by incubation
for 30 min at 37 ºC. After incubation, the plates were
washed 3 times with PBS-T and then the reaction was
revealed with 100 µl of 3,3’,5,5’ tetramethylbenzidine
(TMB) solution for 15 min at room temperature. After
stopping the reaction with 50 µl of 1 M H2SO4, the
plates were read with an ELISA reader (LP400,
Diagnostics Pasteur, France) at 450 nm with or
without the reference at 620 nm. The commercially
available diagnostic kit was studied according to the
manufacturer’s instructions. For testing the specificity
of the reaction, an inhibition test was carried out in 2
steps using antitetanus toxoid standards and human
sera with predefined antitetanus toxoid concentrations.
The predefinition of these sera was performed by the
in-house antitetanus ELISA after its validation
experiment was regarded as successful. Various
concentrations of tetanus toxoid and diphtheria toxoid
were prepared in PBS-1%BSA and then added to
appropriate wells at a volume of 50 µl. Except for the
blank, to the wells was added 50 µl of antitetanus
toxoid standard at 2 IU/ml. The subsequent steps of the
ELISA were performed as described above. For
evaluation of inhibition, 4 different human sera with
predefined antitetanus toxoid concentrations were also
used. After adding tetanus or diphtheria toxoids as
mentioned above, the human sera, diluted finally to
1/100 in PBS-1%BSA, were added to appropriate wells
at a volume of 50 µl. The subsequent steps of the
ELISA were performed as described above.
Statistical analysis. Regression-correlation analysis
was performed for the evaluation of the in-house ELISA.
Inter- or intra-assay coefficients of variation (CV) were
calculated and used for the quality control of the in-house
ELISA. Calculations were performed with SPSS for
Windows version 10.0.
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Results
In the first step, 5 different standards (2, 1, 0.5, 0.2
and 0.1 IU/ml) of the tetanus antitoxoid (supplied as
ready-to-use standards within the Virotech kit) and
blanks were assayed in parallel using both the in-house
ELISA system and the commercial ELISA kit. Both systems
revealed a statistically significant and high linearity
between OD 450/620 nm values and the antitoxoid
concentrations (r2 = 0.956, P = 0.001 and r2 = 0.960, P
= 0.001 respectively). In the second step, tetanus
antitoxoid was prepared at various concentrations in PBS1%BSA by 2-fold dilutions from 1 to 0.0078 IU/ml using
the 5 IU/ml ready-to-use tetanus anti toxoid standard. A
statistically significant and high correlation (P = 0.003, r2
= 0.958) between antitetanus toxoid concentrations and
OD 450/620 nm values was observed (Figure 1). The
2
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Figure 1. Analytical sensitivity of the in-house antitetanus toxoid ELISA.
There is a statistically significant and high correlation between
the antitetanus toxoid concentrations and OD 450/620 nm
values obtained (P = 0.003, r2 = 0.958). Data are the means
of duplicate wells.

analytical sensitivity of the in-house ELISA was less than
0.008 IU/ml because 0.008 IU/ml produced an OD value
(0.172) higher than the cut-off value (0.162). The cutoff value was determined by adding 3 standard deviations
(3 x 0.023) to the mean optical density (0.093) obtained
when the zero standard was assayed 4 times. The quality
control of the in-house ELISA was checked by analyzing
its intra- and inter-assay coefficients of variation (CV).
For the tested concentrations the intra- and inter-assay
CV values were between 0.8 and 4.1% and between 2.2
and 8.6% respectively (Table).
The specificity of the in-house ELISA was analyzed by
testing the inhibitory effect of the tetanus toxoid both on
the antitetanus toxoid standards and on human sera with
predefined antitetanus toxoid concentrations. Tetanus
toxoid inhibited the binding activity of antitetanus toxoid
standard at 2 IU/ml in a concentration-dependent manner
(Figure 2a). The OD read for the dilutions of tetanus
2
toxoid varied significantly (r = 0.7861, P = 0.024) and
pointed to an inversely proportional relationship.
However, an inhibitory effect was not observed (r2 =
0.2398, P > 0.05) with the irrelevant antigen, diphtheria
toxoid, even at a concentration of 5 µg/ml (Figure 2a). To
determine whether this specificity was also applicable to
human sera, a similar assay procedure was performed
using 4 different sera, which were then tested in
duplicate. Although tetanus toxoid inhibited the binding
activity of antitoxoid antibodies in sera in a concentrationdependent manner, no effect could be detected for the
diphtheria toxoid, indicating the high specificity of the inhouse ELISA (Figure 2b).
Two ELISA systems were studied simultaneously with
40 different human sera diluted to 1/100 in order to
compare the performances of both ELISA systems with
human sera. A significant correlation (Pearson correlation
coefficient, r = 0.93; P < 0.01) was observed between
the antitetanus levels measured with 2 different ELISA
systems (Figure 3).

Table. Intra- and inter-assay coefficients of variation (CV) of the in-house antitetanus toxoid ELISA.
Standard (IU/ml)*
1
0.5
0.125
0.0625

Intra-assay CV% (n = 4)

Inter-assay CV% (n = 4)

1.6
0.8
4.1
1.9

3.6
2.2
8.6
4.5

* Antitetanus toxoid standard as supplied by a commercial kit (Virotech)
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Figure 2. Specifity testing of the in-house ELISA by inhibitory reaction. Tetanus toxoid inhibited the binding activity of 2
IU/ml antitetanus toxoid standard (A) and various human sera containing different levels of antitetanus toxoid
antibodies (B) in a concentration-dependent manner. However, inhibition was not observed when a nonspecific
antigen, diphtheria toxin, was used, even at a high concentration of 5 µg/ml. Data are the means of duplicate wells
(TT: tetanus toxoid, DT: diphtheria toxoid).
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Figure 3. Comparison of the performances of both the Virotech tetanus
ELISA and the in-house tetanus ELISA systems using human
sera. Forty different serum samples were measured for their
antitetanus toxoid concentrations simultaneously with both
systems. A significant correlation (r2 = 0.86, P < 0.01) was
observed between 2 different types of assays. Given values
for both ELISA systems are antitetanus toxoid concentrations
expressed in IU/ml.
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Infection caused by C. tetani does not confer
immunity, and recovery from clinical tetanus does not
result in protection against further attacks. Vaccination
with the formaldehyde treated tetanus toxin is the only
means of protection. It is well known that the level of
protective antitetanus antibodies decreases with age
(12,13) and hence population-based screenings for
tetanus toxoid vaccination coverage according to age or
sex may serve as important clues for population-based
studies. In regard to large-scale population-based
screenings, the test used for the detection of antitetanus
antibodies should be easily and rapidly performed under
simple laboratory conditions, it should be commonly
available and cost-effective (2,4). Although several
methods for the detection of tetanus-toxoid antibodies
are available many are not suitable for population
screenings. ELISA due to its simplicity, ease of automation
and availability is widely used for the determination of
antitetanus antibodies (14-19).
Diagnostic accuracy and comparisons between our inhouse ELISA and the Virotech kit are based on Pearson
coefficients of correlation, and intra- and inter-assay
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coefficients of variation. These statistical parameters are
well defined and generally accepted (20).
In this study we developed an in-house ELISA that can
be used for research as well as population-screening
studies for antitetanus antibodies. After the establishment
of the in-house ELISA we performed several comparison
steps with a commercially available diagnostic antitetanus
kit (Virotech). The validation of our in-house ELISA was
performed using ready-to-use standards with known
concentrations of antitetanus toxoid antibodies of the
Virotech kit. The sensitivity of the in-house ELISA was
less than 0.008 IU/ml (Figure 1). The level of circulating
antibodies against tetanus toxoid, i.e. “protective level”, is
somewhat controversial and is closely related to the
method used for the determination of antitetanus toxoid
antibodies. The “protective level” of 0.01 IU/ml is defined
for in vivo, i.e. neutralization, tests. This level does not
reflect the “protective level” determined with in vitro
tests including ELISA. The use of a level of antibody
determined in vitro that is equivalent to 0.01 IU/ml
determined in vivo is advised; taking this into account,
0.1 IU/ml is usually suggested as safe (2). When the
protective cut-off value of antitetanus toxoid antibodies
(>0.1 IU/ml) is considered the critical demarcation point
for serological evaluation, the tested concentration range
around this cut-off value and their respective ODs
displayed a higher correlation coefficient at a statistically
significant level for the Virotech kit (r = 0.999, P =
0.001) and for the in-house ELISA (r = 0.998, P =
0.002). According to these results, we assume that the
in-house ELISA is as precise as the Virotech kit in
diagnosing the cut-off value for the antitetanus immunity.
In order to assess the quality, i.e. reproducibility, of
our in-house ELISA, both intra- and inter-assay CV values
were determined under the same experimental
conditions. As shown in Table, we obtained quite
satisfactory levels of CV for the tested concentrations.
Even the highest CV value was less than 10%, which
indicated that our in-house ELISA is highly reproducible at
significant levels. The low CV values we obtained may be
regarded as a good reflection of assay precision (21).
The specificity of the in-house ELISA was analyzed by
an inhibition test using specific antigen. In addition,
diphtheria toxoid was used in order to determine whether
any inhibition by an irrelevant antigen for the
experimental designs occurs. It was clearly demonstrated
that an inhibitory effect was observed only with the

specific antigen (Figure 2). Therefore, the reaction
obtained in this assay format was directly related and
proportional to the amount of anti toxoid antibodies
present in samples, favoring a specific reaction that could
be inhibited only by tetanus toxoid.
In order to evaluate the performance of our in-house
ELISA with human sera we performed a comparison test
with the Virotech kit by measuring the antitetanus toxoid
antibody levels of 40 different human sera (Figure 3).
The measured antibody levels with both systems revealed
a statistically significant (P < 0.01) correlation (r = 0.93).
Our study results about the in-house developed
antitetanus toxoid ELISA demonstrate an important data
collection that has been verified at each step with a wellknown and commonly used commercially available kit
(Virotech).
The ELISA developed and validated for its specificity,
sensitivity and analytical measuring range is a simple
method for the determination of antitetanus toxoid
antibodies. It is much more satisfactory and displays a
correlation coefficient close to one at the demarcation
value for the antitetanus toxoid that is referred to as the
protective level, thus providing an important and costeffective tool for mass screenings of certain age groups
or genders.
In summary, the results suggested that the in-house
developed antitetanus toxoid ELISA is as reliable and precise
as the well-known and commercially available Virotech kit
for determining antitetanus toxoid antibodies in human
sera. The main advantage of our in-house ELISA is its
reliability and cost-effectiveness. In addition, according to
the working principle of the in-house ELISA system
developed, it can measure antitetanus toxoid without being
affected by the species or isotype of the specific antibody
because the specific antibody in the sample binds the
antigen (tetanus toxoid) on the solid phase with one of its
Fab fragments while binding biotinylated specific antigen
with the other. Therefore, the system developed in our
laboratory enabled us not only to measure antitetanus
toxoid from human sera but also antitetanus toxoid from
other species, such as mice, successfully.
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